Nestor Girala
The efficacy of hallucinogenic drugs (ayahuasca, psilocybin, LSD, ketamine) in treating depression and addictions is accompanied by intense emotional states and mystical-type experiences, including feelings of oneness, transcendence, ineffability, and awe. These common psychopathological elements may mediate the drugs' therapeutic action. The paper reviews literature on subjective experiences during such treatments and compares them with other life-changing experiences, discussing the evolutionary value of these emotions for group cohesiveness and the recalibration of cognitions and emotions.
Research Square
Sean Viña
People who use psychedelics are less likely to seek formal mental health care, including medication and outpatient treatment, even when experiencing high psychological distress. Analyzing data from over 458,000 participants in a national US survey between 2010 and 2018, the study found that as distress levels increase, psychedelic users become even less inclined to use formal care compared to non-users. This suggests a heightened risk of self-medication as psychedelics become more culturally and legally accepted.
medRxiv
Klemens Egger, Daniel Meling, Firuze Polat et al.
preprint
In a double-blind, placebo-controlled pharmaco-fMRI study, 40 meditation practitioners on a three-day retreat received either placebo or buccal DMT-harmine (120 mg each). Meditation alone increased network segregation across several resting-state networks, while DMT-harmine increased functional connectivity within the visual network and between visual and attention networks. Between-group differences showed increased connectivity between visual and salience networks in the DMT-harmine group. No prolonged cortical gradient disruption was observed, indicating a return to typical brain organization shortly after the experience. Meditation reduced connectivity between networks, whereas DMT-harmine increased within- and between-network connectivity, revealing distinct neural mechanisms.
Mika Turkia
preprint
Spiritual attacks reported during Amazonian ayahuasca ceremonies are often dismissed as imaginary, but this article argues they are real subjective experiences involving visions or bodily sensations felt as harmful interventions from an external hostile party. The author proposes that these attacks can be understood as mental representations of fundamental disagreements between two parties, with defenses consisting of methods to maintain stability and resolve negative emotions. This conceptualization aims to improve understanding of a rarely documented and difficult-to-conceptualize phenomenon.
Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al.
preprint
DMT, the psychedelic in ayahuasca, is being studied for depression. In a double-blind, placebo-controlled trial, ayahuasca led to remission in 36% of patients with treatment-resistant depression within one week. A Phase IIa trial reported that 57% of patients with major depressive disorder experienced remission 12 weeks after a single dose of DMT. DMT is naturally produced in the body, but likely at insignificant levels. The idea that DMT is released during death remains unproven. Ayahuasca can cause temporary vomiting but appears generally safe. More research is needed on DMT's therapeutic and biological roles.
Experimental neurology
September 1, 2026
Javier Calleja-Conde, Víctor Echeverry-Alzate, Marina Sanz-Sancristóbal et al.
In a preclinical model of Parkinson's disease, the compound N,N-dimethyltryptamine (DMT), the main psychoactive ingredient in ayahuasca, reduced neuroinflammation and preserved neurons in the nigrostriatal pathway. Treated animals also showed improvements in behavior. These results suggest DMT may have disease-modifying potential for Parkinson's disease, a progressive neurodegenerative disorder marked by loss of dopaminergic neurons and chronic inflammation, for which current treatments only relieve symptoms.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
July 17, 2026
Mauro Scala, Enrico Magrini, Ivana Leccisotti et al.
Suicide remains a leading cause of early death worldwide, and current treatments are limited by slow onset, short durability, or poor tolerability. This narrative review of 34 studies over the past decade examined pharmacological and neuromodulation interventions for suicidal ideation or suicide attempt that are not yet approved for these uses. Across controlled trials, suicidal ideation commonly improved within days to weeks. Some trials reported reductions in suicidal ideation beyond changes in depression scores, suggesting partial independence, though evidence remains inconsistent. Encouraging results were reported for NMDA-related drugs, opioid-system modulation, ayahuasca, and certain neuromodulation techniques, while non-medical cannabis use was associated with worse suicidal ideation trajectories.
Psychopharmacology
July 14, 2026
Helena D Aicher, Joëlle Dornbierer, Luzia Caflisch et al.
A combination of harmine and DMT, the active ingredients in ayahuasca, reduces feelings of embarrassment and shame in healthy men. In a randomized trial with 28 participants, those who received the combination reported significantly less embarrassment when listening to recordings of their own singing compared to those who received a placebo. The treatment also lowered overall shame scores. Harmine alone did not produce these effects. The findings suggest that this compound may help treat psychiatric disorders where negative self-focused emotions play a key role.
Zenodo (CERN European Organization for Nuclear Research)
July 8, 2026
Schüller Thomas
Two works examine the appropriation of Indigenous healing practices. The first, 'Die enteignete Heilerin' (The Expropriated Healer), focuses on the Mazatec shaman Maria Sabina, whose use of psilocybin mushrooms was co-opted by outsiders. The second, 'Vier Enteignungen, ein Muster' (Four Expropriations, One Pattern), compares the appropriation of peyote, ayahuasca, salvia, and iboga, arguing that a common pattern of colonial and capitalist expropriation underlies these cases.
Braz J Psychiatry
July 7, 2026
Alberto Souza Sá Filho, James Oluwagbamigbe Fajemiroye, Antonio Egidio Nardi et al.
The article argues that while ayahuasca has shown promise in early depression research, the field must move beyond initial enthusiasm to address methodological challenges and ethical considerations. It calls for rigorous, well-controlled studies to determine efficacy and safety, and emphasizes the need to understand the specific mechanisms of action. The authors suggest that future research should focus on long-term outcomes, potential risks, and the integration of ayahuasca into broader therapeutic contexts, rather than simply celebrating its potential.